Analysts reiterate bullish ratings on both Valeant Pharmaceuticals Intl Inc (NYSE:VRX) as investors hope that the new Walgreens deal will fill Philidor’s void, and Soligenix Inc (OTCBB:SNGX) amid pipeline updates.

Valeant Pharmaceuticals Intl Inc

Neil Maruoka of Canaccord reiterated a Buy rating on Valeant with a $170 price target after the biopharmaceutical company struck a deal with Walgreens, which the analyst believes is Valeant’s “first significant step in restoring credibility and investor confidence” after fraud allegations. Within the terms of the deal, Walgreens will offer Valeant’s dermatology products at a 10% discount. The 20-year agreement is expected to decrease costs for patients and the company alike.

Pointing to recent fraud allegations that hurt Valeant’s share prices, Maruoka believes “the worst has passed.” He explains, “We believe this deal was as much a move to mend public perception as it was to repair Valeant’s business, and the expected $600 million of savings to the healthcare system should be viewed very positively.”

As the dust settles around the negative publicity, the analyst comments that Valeant does not need to complete further acquisitions to prove it is in healthy financial standing, thanks to its cash flow being used to accelerate deleveraging.

Neil Maruoka has a 25% success rate recommending stocks with a 20.9% average loss per rating. According to TipRanks, 14 analysts are currently bullish on Valeant, 1 is bearish, and 6 remain neutral. The average 12-month price target for the stock is $164.81, marking a 39% potential upside from the stock.

VRX consensus

Soligenix Inc

Grant Zeng of Zacks Small-Cap Research pounded the table on Soligenix Inc, reiterating a Buy rating on the biotech company with a $5 price target, marking over a 400% increase from current levels.

Zeng commented, “We are optimistic about its lead candidates SGX301for CTLC and SGX942 for the treatment of oral mucositis. The Company s oral BDP is in various development stages for a variety of indications, most notably, in pediatric Crohn s disease, where they will be initiating a Phase III study soon for SGX203. SNGX also is developing vaccines using its ThermoVax technology for biodefense.”

According to TipRanks, Grant Zeng has a 0% success rate recommending stocks with a 39.3% average loss per rating. One other analyst is also bullish on Soligenix, also with a $5 price target.